EntreMed, Inc. (Nasdaq:ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, today reported results for the three months and twelve months ended December 31, 2010. For fiscal year 2010, revenues were $3.7 million compared to $5.3 million for fiscal 2009. For the year ended December 31, 2010, the Company reported a net loss of ($9.1 million) or ($0.94) per share, compared to a net loss of ($9.2 million), or ($1.16) per share, for fiscal year 2009. As of December 31, 2010, the Company had cash and short-term investments of approximately $4.9 million. Revenues for the fourth quarter ended December 31, 2010 were $3.7 million compared to $1.6 million for the fourth quarter ended December 31, 2009.
EntreMed, Inc., a clinical-stage pharmaceutical company, engages in developing therapeutics for the treatment of cancer and inflammatory diseases.
Enzon Pharmaceuticals, Inc. (Nasdaq:ENZN) announced that Richard C. Mulligan, Ph.D., has been appointed Vice-Chairman of the Board of Directors, effective immediately. Dr. Mulligan, the Mallinckrodt Professor of Genetics at Harvard Medical School and Director of the Harvard Gene Therapy Initiative, was elected to Enzon�s Board of Directors at the 2009 annual meeting of stockholders.
Enzon Pharmaceuticals, Inc. is a biotechnology company dedicated to the research and development of innovative therapeutics for cancer patients with high unmet medical needs. Enzon�s drug-development programs utilize two platforms � Customized PEGylation Linker Technology (Customized Linker Technology(R)) and third-generation mRNA-targeting agents utilizing the Locked Nucleic Acid (LNA) technology.
National Health Partners, Inc. (NHPR)
Healthcare is one of the top social and economic problems facing Americans today. The rising cost of medical care and health insurance is impacting the livelihood of many Americans in one way or another. The inability to pay for necessary medical care is no longer a problem affecting only the uninsured, but is increasingly becoming a problem for those with health insurance as well. The problems with health care are affecting many Americans: the uninsured and insured, the unemployed and working, children and retirees, single individuals and families. From lack of access to preventative care and the high cost of medical treatment, there are many health care problems facing Americans.
National Health Partners, Inc. is a national healthcare savings organization that provides discount healthcare membership programs to uninsured and underinsured people through a national healthcare savings network called �CARExpress.� CARExpress is one of the largest networks of hospitals, doctors, dentists, pharmacists and other healthcare providers in the country and is comprised of over 1,000,000 medical professionals that belong to such PPOs as CareMark and Aetna. The company�s primary target customer group is the 47 million Americans who have no health insurance of any kind. The company�s secondary target customer group includes the millions of Americans who lack complete health insurance coverage.
National Health Partners, Inc. recently announced the launch of a new network marketing program by one of its strategic partners, Xpress Healthcare, LLC. Xpress Healthcare has teamed up with CARExpress in an effort to revolutionize the discount healthcare industry while at the same time bringing financial freedom to families across the nation. Xpress Healthcare has developed a first-class business platform that will enable brokers to develop their own business while generating strong monthly cash flows.
By the end of the second quarter of 2011, Xpress Healthcare anticipates adding over 100 new brokers both participating in and promoting the CARExpress program and should enroll over 2,500 new members; the company also expects its growth to accelerate in the 3rd quarter as it anticipates recruiting an additional 200 new brokers which should generate over 10,000 new CARExpress sales. According to the National Health Partners, Strong Sales are projected for 2nd Quarter From this New Strategic Partnership.
For more information about National Health Partners, Inc visit its website www.nationalhealthpartners.com
EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced financial results for the fourth quarter and full year ended December 31, 2010. Total revenue for the fourth quarter 2010 was EUR 8.0 million (USD 10.8 million), as compared to EUR 8.1 million (USD 11.9 million) for the fourth quarter 2009. Gross profit for the fourth quarter 2010 was EUR 3.0 million (USD 4.1 million), compared to EUR 3.7 million (USD 5.4 million) for the year ago period. Gross profit margin was 37.6% in the fourth quarter 2010, compared to 45.5% in the year ago period. The change in the gross profit margin was attributed to shift in the product mix sold in the fourth quarter of 2010 to a lower percentage of Ablatherm-HIFU devices.
No comments:
Post a Comment